Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
August 14 2017 - 7:30AM
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage
biopharmaceutical company developing novel therapeutics for
difficult to treat cancers, announced today that Ivan Bergstein,
M.D., Stemline’s CEO, will present at the 2017 Wedbush PacGrow
Healthcare Conference on Tuesday, August 15, 2017 at 8:00 AM ET.
The conference is being held at the Le Parker Meridien in New York,
NY. A webcast of the presentation can be viewed on the company's
website at www.stemline.com.
About Stemline Therapeutics Stemline
Therapeutics, Inc. is a clinical stage biopharmaceutical company
developing novel therapeutics for difficult to treat cancers.
SL-401 is a targeted therapy directed to the interleukin-3 receptor
(CD123), a cell surface receptor overexpressed on BPDCN and a
variety of other hematologic cancers. SL-401 was granted
Breakthrough Therapy Designation (BTD) for the treatment of
patients with BPDCN. A pivotal Phase 2 trial with SL-401 in BPDCN
has completed enrollment in Stages 1, 2 and 3 of the trial; to
ensure ongoing patient access to SL-401, an additional cohort,
Stage 4, is enrolling. Additional Phase 1/2 trials are assessing
SL-401 in patients with other malignancies including
myeloproliferative neoplasms (MPN) (focused on chronic
myelomonocytic leukemia [CMML] and myelofibrosis [MF]), acute
myeloid leukemia (AML), and multiple myeloma, as a single agent or
in combination with other agents. SL-801, a novel oral small
molecule reversible inhibitor of XPO1, is enrolling patients with
advanced solid tumors in a Phase 1 trial. SL-701, an
immunotherapeutic, has completed dosing of patients with
second-line glioblastoma in a Phase 2 trial and patients are being
followed for outcomes including survival.
Forward-Looking Statements Some of the
statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The factors that could cause our
actual results to differ materially include: the success and timing
of our clinical trials and preclinical studies for our product
candidates, including site initiation, institutional review board
approval, scientific review committee approval, patient accrual,
safety, tolerability and efficacy data observed, and input from
regulatory authorities including the risk that the FDA or other
ex-U.S. national drug authority ultimately does not approve any of
our product candidates; our plans to develop and commercialize our
product candidates; market acceptance of our products;
reimbursement available for our products; our available cash and
investments; our ability to obtain and maintain intellectual
property protection for our product candidates; our ability to
manufacture; the performance of third-party manufacturers, clinical
research organizations, clinical trial sponsors and clinical trial
investigators; and other risk factors identified from time to time
in our reports filed with the Securities and Exchange Commission.
Any forward-looking statements set forth in this press release
speak only as of the date of this press release. We do not intend
to update any of these forward-looking statements to reflect events
or circumstances that occur after the date hereof.
Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Apr 2023 to Apr 2024